ArticleNPJ digital medicine2026
AEGIS: an operational infrastructure for post-market governance of adaptive medical AI under US and EU regulatory frameworks.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Medical AI requires governance preserving safety during continuous improvement. FDA Predetermined Change Control Plans (PCCP) and EU post-market surveillance address iterative updates but lack operational tooling. We present AEGIS, an internal governance and post-market-monitoring infrastructure designed to support the documentation of predetermined governance pathways for PCCP and Medical Devices Regulation alignment. AEGIS comprises dataset assimilation and retraining, model monitoring, and conditional decision-making modules. It utilizes a four-category taxonomy (APPROVE, CONDITIONAL APPROVAL, CLINICAL REVIEW, REJECT) and an independent ALARM signal. Instantiating AEGIS for sepsis prediction (PhysioNet) and brain-tumor segmentation (BraTS) exercised all decision categories, successfully routing failures to the critical REJECT + ALARM state (no deployable model; released model at risk). On real cross-site data, drift detection ROC-AUC rose from 0.82 to 1.00, reliably triggering near 500-patient batches with zero false alarms. This proof-of-concept utilizes illustrative clinical models; drift scoring quantifies covariate shift only, leaving concept drift for future work.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.